Skip to main content
Clinical Trials/NCT03281005
NCT03281005
Completed
Not Applicable

Calibration of Visual Function Evaluation Tests in Patients With Severe Vision Loss

Astellas Pharma Inc1 site in 1 country18 target enrollmentNovember 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Retinitis Pigmentosa
Sponsor
Astellas Pharma Inc
Enrollment
18
Locations
1
Primary Endpoint
Color flash VEP test in Part 1A and 2
Status
Completed
Last Updated
last year

Overview

Brief Summary

The objective of this study is to develop the comprehensive visual function evaluation method in severe visually impaired patient

Detailed Description

This study is a prospective observational study which consists of 4 Parts; Part 1A, 1B, 2 and 3. Part 1A has been conducted on 6 subjects diagnosed with retinitis pigmentosa. Additional examination will be performed using alternative devices imported outside Japan on subjects who completed Part 1A and re-consented (Part 1B). Based on the interim result of Part 1A, Part 2 will be conducted on another 6 subjects with retinitis pigmentosa with improved methodology and the devices used in Part 1B. Part 3 will be conducted in 6 healthy volunteers to obtain comparative data using devices used in Part 1B.

Registry
clinicaltrials.gov
Start Date
November 1, 2017
End Date
November 21, 2019
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Subjects who have participated in any other clinical trial or clinical study involving visual function evaluation within 6 months
  • Subjects who have history of surgery, past history, and complications (cardiac/ hepatic/ renal/ respiratory/ hematological diseases, optic nerve diseases causing marked loss of visual field, and uveitis etc.) that potentially affect evaluation and safety of the study
  • Pregnant women
  • Subjects who are judged that continuation of the study is difficult during the study period
  • Subjects who are employed by the company sponsoring this study, an organization or institution related to this study

Outcomes

Primary Outcomes

Color flash VEP test in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function

Color flash VEP test in Part 1B and 3

Time Frame: Day 1

To assess the visual function

White flash VEP test in Part 1B and 3

Time Frame: Day 1

To assess the visual function

Electrically evoked response (EER) test in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function

EER test in Part 1B and 3

Time Frame: Day 1

To assess the visual function

White flash electroretinography test in Part 1A, 1B, 2 and 3

Time Frame: Day 1

To assess the visual function

Pupillary function test in Part 2

Time Frame: Up to week 8

To assess the visual function

Pupillary function test in Part 1B and 3

Time Frame: Day 1

To assess the visual function

Full field stimulus threshold testing (FST) in Part 2

Time Frame: Up to week 8

To assess the visual function

FST in Part 1B

Time Frame: Day 1

To assess the visual function

Slit-lamp microscopy in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function

Slit-lamp microscopy in Part 1B and 3

Time Frame: Day 1

To assess the visual function

Optical Coherence Tomography (OCT) test in Part 1A and 2

Time Frame: Day 1

To assess the visual function

Visual acuity test with Early Treatment Diabetic Retinopathy Study (ETDRS) in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function

Visual acuity test with ETDRS in Part 1B

Time Frame: Day 1

To assess the visual function

The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function and the quality of life (QOL)

The 11-item National Eye Institute Visual Function Questionnaire (NEI VFQ-11) in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function and QOL

Nottingham Adjustment Scale Japanese Version (NAS-J) in Part 1A and 2

Time Frame: Up to week 8

To assess the psychological adjustment

Daily living task dependent on vision (DLTV) in Part 1A and 2

Time Frame: Up to week 8

To assess QOL

Table test in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function

Metropsis test in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function

Low vision evaluator (LoVE) in Part 1A

Time Frame: Up to week 8

To assess the visual function

White flash visual evoked potential (VEP) test in Part 1A and 2

Time Frame: Up to week 8

To assess the visual function

Study Sites (1)

Loading locations...

Similar Trials